Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia - Denmeade, SR; Egerdie, B; Steinhoff, G (Eur Urol, 2011)
et al.